A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

• Status: Not yet recruiting
• Trial end date: 2023-03-30
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy, safety and pharmacokinetic characteristics of HR070803 in the treatment of advanced esophageal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Criteria

Inclusion Criteria:

1. ECOG performance status 0 or 1

2. Histologically confirmed advanced esophageal carcinoma

3. At least one measurable lesion is present according to the efficacy evaluation criteria for solid tumors (RECIST 1.1)

4. Able and willing to provide a written informed consent

Exclusion Criteria:

1. The tumor obviously invades adjacent organs of esophageal lesions

2. BMI≤18.5 kg/m2 or weight loss ≥10% within 2 months prior to screening

3. Subjects with unresolved adverse effects of prior therapy at the time of enrolment

4. Subjects who had received anti-tumor treatments such as surgery, chemotherapy, radiotherapy recently